137 related articles for article (PubMed ID: 8988124)
1. Occlusive paromomycin for cutaneous leishmaniasis.
Bell SA; Schaller M; Röcken M
Lancet; 1997 Jan; 349(9044):29. PubMed ID: 8988124
[No Abstract] [Full Text] [Related]
2. Occlusive paromomycin for cutaneous leishmaniasis.
Bryceson AD
Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342
[No Abstract] [Full Text] [Related]
3. Allergic contact dermatitis caused by paromomycin.
Veraldi S; Benzecry V; Faraci AG; Nazzaro G
Contact Dermatitis; 2019 Nov; 81(5):393-394. PubMed ID: 31231805
[No Abstract] [Full Text] [Related]
4. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
5. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
7. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Soto J; Soto P; Ajata A; Luque C; Tintaya C; Paz D; Rivero D; Berman J
Clin Infect Dis; 2019 Feb; 68(5):844-849. PubMed ID: 30260376
[TBL] [Abstract][Full Text] [Related]
8. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
9. Fluconazole for the treatment of cutaneous leishmaniasis.
Zvulunov A; Klaus S; Vardy D
N Engl J Med; 2002 Aug; 347(5):370-1; author reply 370-1. PubMed ID: 12151480
[No Abstract] [Full Text] [Related]
10. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
Schallreuter KU; Lemke KR
Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
[TBL] [Abstract][Full Text] [Related]
11. Unsuccessful treatment of cutaneous leishmaniasis by Leishmania infantum with topical paromomycin.
Veraldi S; Benzecry Mancin V; Faraci AG; Nazzaro G
Int J Dermatol; 2020 Jul; 59(7):e251-e252. PubMed ID: 31975375
[No Abstract] [Full Text] [Related]
12. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole.
Chacko A; Joseph M; Feltis T; Morris SK
Am J Trop Med Hyg; 2016 Oct; 95(4):793-794. PubMed ID: 27549634
[TBL] [Abstract][Full Text] [Related]
13. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause G; Kroeger A
Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
[No Abstract] [Full Text] [Related]
14. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.
Asilian A; Jalayer T; Nilforooshzadeh M; Ghassemi RL; Peto R; Wayling S; Olliaro P; Modabber F
Bull World Health Organ; 2003; 81(5):353-9. PubMed ID: 12856053
[TBL] [Abstract][Full Text] [Related]
15. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Grogl M; Schuster BG; Ellis WY; Berman JD
J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
17. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.
Neva FA; Ponce C; Ponce E; Kreutzer R; Modabber F; Olliaro P
Trans R Soc Trop Med Hyg; 1997; 91(4):473-5. PubMed ID: 9373659
[TBL] [Abstract][Full Text] [Related]
18. Leishmaniasis chemotherapy--challenges and opportunities.
Croft SL; Olliaro P
Clin Microbiol Infect; 2011 Oct; 17(10):1478-83. PubMed ID: 21933306
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Leishmaniasis in an American Adolescent Returning From Israel.
Ganjaei KG; Lawton K; Gaur S
J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e178-e181. PubMed ID: 29878238
[TBL] [Abstract][Full Text] [Related]
20. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
Flaig MJ; Rupec J; Ruzicka T; Rupec RA
Hautarzt; 2007 Aug; 58(8):689-90, 692. PubMed ID: 17676349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
